Regeneron Pretax Profit Margin vs Operating Profit Margin Analysis
REGN Stock | USD 937.61 34.13 3.78% |
Regeneron Pharmaceuticals financial indicator trend analysis is much more than just breaking down Regeneron Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regeneron Pharmaceuticals is a good investment. Please check the relationship between Regeneron Pharmaceuticals Pretax Profit Margin and its Operating Profit Margin accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
Pretax Profit Margin vs Operating Profit Margin
Pretax Profit Margin vs Operating Profit Margin Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regeneron Pharmaceuticals Pretax Profit Margin account and Operating Profit Margin. At this time, the significance of the direction appears to have totally related.
The correlation between Regeneron Pharmaceuticals' Pretax Profit Margin and Operating Profit Margin is 1.0. Overlapping area represents the amount of variation of Pretax Profit Margin that can explain the historical movement of Operating Profit Margin in the same time period over historical financial statements of Regeneron Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Regeneron Pharmaceuticals' Pretax Profit Margin and Operating Profit Margin is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pretax Profit Margin of Regeneron Pharmaceuticals are associated (or correlated) with its Operating Profit Margin. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Profit Margin has no effect on the direction of Pretax Profit Margin i.e., Regeneron Pharmaceuticals' Pretax Profit Margin and Operating Profit Margin go up and down completely randomly.
Correlation Coefficient | 1.0 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Pretax Profit Margin
Operating Profit Margin
Most indicators from Regeneron Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.At this time, Regeneron Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 3rd of May 2024, Tax Provision is likely to grow to about 584.1 M, while Sales General And Administrative To Revenue is likely to drop 0.26.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 4.7B | 5.6B | 7.1B | 7.4B | Cost Of Revenue | 2.4B | 1.6B | 883.7M | 927.9M |
Regeneron Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Regeneron Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Regeneron Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 14.8B | 17.2B | 25.4B | 29.2B | 33.1B | 34.7B | |
Total Current Liabilities | 1.8B | 2.8B | 3.5B | 3.8B | 3.4B | 3.6B | |
Total Stockholder Equity | 11.1B | 11.0B | 18.8B | 22.7B | 26.0B | 27.3B | |
Property Plant And Equipment Net | 2.9B | 3.2B | 3.5B | 3.8B | 4.1B | 4.4B | |
Net Debt | (903.9M) | 502M | (185.9M) | (404.5M) | (27.1M) | (28.5M) | |
Retained Earnings | 7.4B | 10.9B | 19.0B | 23.3B | 27.3B | 28.6B | |
Cash | 1.6B | 2.2B | 2.9B | 3.1B | 2.7B | 2.9B | |
Non Current Assets Total | 4.2B | 4.4B | 4.9B | 7.1B | 13.6B | 14.3B | |
Non Currrent Assets Other | 531.8M | 328.9M | 555.2M | (4.7B) | 444.1M | 466.3M | |
Cash And Short Term Investments | 6.5B | 6.7B | 12.5B | 14.3B | 10.8B | 11.4B | |
Net Receivables | 2.7B | 4.1B | 6.0B | 5.3B | 5.7B | 6.0B | |
Common Stock Shares Outstanding | 114.6M | 115.1M | 112.2M | 113.5M | 113.7M | 75.4M | |
Liabilities And Stockholders Equity | 14.8B | 17.2B | 25.4B | 29.2B | 33.1B | 34.7B | |
Non Current Liabilities Total | 1.9B | 3.3B | 3.2B | 2.7B | 3.7B | 3.9B | |
Other Current Assets | 959.3M | 1.2B | 332.4M | 933M | 386.6M | 203.9M | |
Other Stockholder Equity | 3.7B | 102.9M | (173.4M) | (404M) | (1.2B) | (1.1B) | |
Total Liab | 3.7B | 6.1B | 6.7B | 6.6B | 7.1B | 7.5B | |
Total Current Assets | 10.6B | 12.8B | 20.5B | 22.1B | 19.5B | 20.5B | |
Short Long Term Debt Total | 713.9M | 2.7B | 2.7B | 2.7B | 2.7B | 2.8B | |
Other Current Liab | 781.1M | 122.4M | 1.7B | 2.0B | 2.4B | 2.5B | |
Accounts Payable | 418.1M | 475.5M | 564M | 589.2M | 606.6M | 636.9M | |
Property Plant And Equipment Gross | 2.9B | 3.2B | 4.9B | 5.4B | 6.1B | 6.4B | |
Accumulated Other Comprehensive Income | 21.1M | 29.3M | (26.2M) | (238.8M) | (80.9M) | (76.9M) | |
Short Term Investments | 1.6B | 1.4B | 2.8B | 4.6B | 8.1B | 8.5B | |
Inventory | 1.4B | 1.9B | 2.0B | 2.4B | 2.6B | 2.7B | |
Other Liab | 889M | 635.5M | 515.3M | 707.8M | 814.0M | 854.7M | |
Other Assets | 913.3M | 2.8B | 555.2M | 747.6M | 859.7M | 902.7M | |
Property Plant Equipment | 2.9B | 3.2B | 3.5B | 3.8B | 4.3B | 4.5B | |
Current Deferred Revenue | 591.7M | 577.7M | 442M | 547.7M | 458.9M | 481.8M | |
Net Tangible Assets | 11.1B | 11.0B | 18.8B | 21.7B | 25.0B | 26.3B | |
Retained Earnings Total Equity | 7.4B | 10.9B | 19.0B | 23.3B | 26.8B | 28.1B | |
Long Term Debt Total | 713.9M | 2.0B | 2.0B | 2.0B | 2.3B | 2.4B | |
Capital Surpluse | 4.4B | 6.7B | 8.1B | 9.9B | 11.4B | 12.0B | |
Long Term Investments | 3.3B | 3.1B | 6.8B | 6.6B | 5.4B | 3.3B |
Currently Active Assets on Macroaxis
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Earnings Share 34.77 | Revenue Per Share 122.935 | Quarterly Revenue Growth 0.006 | Return On Assets 0.0849 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.